Theravance Biopharma (TBPH) Revenue (2013 - 2026)
Theravance Biopharma (TBPH) posted quarterly Revenue of $17.7 million for Q1 2026, up 15.02% year-over-year from $15.4 million in Q1 2025, and down 61.43% quarter-over-quarter from $45.9 million in Q4 2025.
Theravance Biopharma (TBPH) Revenue (2013 - 2026) Analysis & Trends
Theravance Biopharma (TBPH) has reported Revenue for 14 consecutive years, with $17.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Revenue rose 15.02% year-over-year to $17.7 million; the TTM figure through Mar 2026 stood at $109.8 million (up 68.2% YoY), while the FY2025 annual figure was $7.5 million, down 88.35% from the prior year.
- Revenue eased to $17.7 million in Q1 2026 per TBPH's latest filing, from $45.9 million in the prior quarter.
- Across five years, Revenue topped out at $45.9 million in Q4 2025 and bottomed at $10.4 million in Q1 2023.
- Historically, Revenue has averaged $17.5 million across 5 years, with a median of $15.4 million in 2025.
- Annual changes were most pronounced in 2023 — Revenue fell 21.06% — and 2025, when it jumped 144.7%.
- Theravance Biopharma's Revenue stood at $14.6 million in 2022, then increased by 19.91% to $17.6 million in 2023, then rose by 6.77% to $18.8 million in 2024, then surged by 144.7% to $45.9 million in 2025, then tumbled by 61.43% to $17.7 million in 2026.
- Business Quant data shows TBPH's Revenue at $17.7 million in Q1 2026, $45.9 million in Q4 2025, and $20.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.56 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.71 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3,001.92 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 674.14 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.29 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 425.49 Mn |
| 10 | Theravance Biopharma | 880.59 Mn | 492.93 Mn | - | 20.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 20.73 Mn |
| Mar 31, 2026 | 17.70 Mn |
| Dec 31, 2025 | 45.89 Mn |
| Sep 30, 2025 | 19.99 Mn |
| Jun 30, 2025 | 26.20 Mn |
| Mar 31, 2025 | 15.39 Mn |
| Dec 31, 2024 | 18.75 Mn |
| Sep 30, 2024 | 16.87 Mn |
| Jun 30, 2024 | 14.26 Mn |
| Mar 31, 2024 | 14.50 Mn |
| Dec 31, 2023 | 17.57 Mn |
| Sep 30, 2023 | 15.69 Mn |
| Jun 30, 2023 | 13.75 Mn |
| Mar 31, 2023 | 10.42 Mn |
| Dec 31, 2022 | 14.65 Mn |
| Sep 30, 2022 | 12.45 Mn |
| Jun 30, 2022 | 11.05 Mn |
| Mar 31, 2022 | 13.20 Mn |
| Dec 31, 2021 | 14.95 Mn |
| Sep 30, 2021 | 13.19 Mn |